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Background: The PREVEND IT trial reported on a high cardiovascular (CV) event rate in subjects with a baseline
urinary albumin excretion (UAE) rate of ≥50 mg/24 h. Here, we report on the observed 10-year CV outcome
of this population and compare this with the predicted Framingham Risk Score (FRS). In addition, we evaluated
the effect of four years of fosinopril treatment on this relation.
Methods and results: From the PREVEND IT cohort, 833 subjects without history of CV disease, randomized to
fosinopril (N = 412) or placebo (N= 421), were studied. The primary endpoint included CV mortality and ad-
judicated hospitalization for CV disease during a 10-year follow-up period. Mean agewas 51± 12 years and 65%
weremales, while prevalence of diabetes (2.6%) and use of CV drugs (3.5%)was low. Subjectswere categorized to
high UAE (≥50 mg/24 h) or low UAE (b50 mg/24 h). After 10 years of follow-up, the event rate in the high UAE
groupwas almost twice as high as predicted by the FRS (29.5% vs. 17.2%). Treatment for four yearswith fosinopril
reduced the event rate to comparable levels of that predicted by FRS. The addition of UAE≥50 mg/24h to the FRS
improved the Integrated Discrimination Improvement (P = 0.033) and increased the area under the curve by
0.54% (P = 0.024).
Conclusions: The 10-year CV risk of subjectswith an elevatedUAE (≥50 mg/24 h) is substantially underestimated
by the FRS. Treatment with fosinopril successfully reduced this increased event rate to FRS-predicted CV
risk.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cardiovascular (CV) diseasemay be predicted by a variety of clinical,
biochemical, and surrogate risk factors. Of these, endothelial dysfunc-
tion has also been linked to the development of atherogenesis [1,2]. In-
creased levels of urinary albumin excretion (UAE) do not only provide
an indication of early renal dysfunction, but functions also as a markercially supported by grant E.013
03 of the Netherlands Heart
Squibb.
n, University Medical Center
01, Hanzeplein 1, 9713 GZ,
31 503611347.
).
ts of the reliability and freedom
retation.
land Ltd. This is an open access articlof endothelial dysfunction [3].Many trials have reported on a high prev-
alence of elevated UAE not only in high risk subjects suffering from dia-
betes [4,5], renal failure [6], or heart failure [7,8], but also in subjects
from the general population [9]. An increased UAE was in every cohort
associated with worse outcome. Recently, the Prevention of REnal and
Vascular ENd-stage Disease Intervention Trial (PREVEND IT) conﬁrmed
these results and reported on a CV event rate of almost 30% in subjects
with a baseline UAE ≥50 mg/24 h after 10 years of follow-up [10].
Some have proposed that UAE may be a useful surrogate marker for
CV disease. It is unclear whether conventional CV risk prediction
models, like the Framingham Risk Score (FRS) can be used in a popula-
tion with albuminuria [11,12]. In addition, it remains unclear whether
the addition of UAE could signiﬁcantly improve prognostic performance
of the FRS. In this analysis, we retrospectively investigate the quality of
the CV risk estimations by the FRS by comparing it to the observed out-
come in PREVEND IT.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1. Study population
The studywas performed using data of the PREVEND IT study,which
has been described elsewhere [10,13]. Brieﬂy, the aim of PREVEND IT
was to assess the value of albuminuria as an indicator of increased CV
risk in the general population. The key entry criteria of PREVEND IT
were persistent microalbuminuria (one urinary albumin concentration
≥10 mg/L in an early morning spot urine test and at least one 15 to
300 mg/24 h in two 24 h urine samples), absence of antihypertensive
and lipid-lowering medication, a blood pressure of b160/100 mm Hg
and a total cholesterol of b8.0 mmol/L or b5.0 mmol/L in the case of
previous myocardial infarction. From April 1998 to June 1999, 864 sub-
jects were included in the PREVEND IT and were randomized to 20 mg
fosinopril ormatching placebo for the duration of four years (referred to
as “active trial period”). At the end of this four year period, all subjects
were taken off study medication and returned to the care of their
general practitioners. Follow-up time was extended for an additional
6.0 years after the active trial period was ended, resulting in a total
follow-up time of 10.0 years. To evaluate the FRS in our sample, we ex-
cluded subjects in which the variables of FRSweremissing (N=2, both
missing values of HDL-cholesterol) or subjects with a history of CV
disease (N = 29). Finally, a total of 833 subjects were eligible for the
current analysis. An independent data and safetymonitoring committee
regularly monitored the progress of PREVEND IT during the entire
follow-up period. The study was approved by the institutional medical
ethics committee and conducted in accordance with the ethical guide-
lines of the 1975 Declaration of Helsinki. Informed consent was obtain-
ed from all subjects before randomization.
2.2. Endpoint collection and follow-up
The composite primary endpoint is the combined incidence of CV
mortality and hospitalization for CV morbidity. CV morbidity was de-
ﬁned as hospitalization for documented nonfatal myocardial infarction
or myocardial ischemia, heart failure, peripheral artery disease, and/or
cerebrovascular accident. These endpoints are the same as for the FRS
for general CV disease [14]. Follow-up for all surviving subjects after
the active trialwas collected via personal communication and electronic
hospital ﬁles. Data on mortality were retrieved from the municipal reg-
ister. Cause of death was obtained through the Dutch Central Bureau of
Statistics and was coded according to the 10th revision of the Interna-
tional Classiﬁcation of Diseases. Follow-up on hospitalization for CV
morbidity was derived from records held by PRISMANT, the Dutch na-
tional registry of hospital discharge diagnoses [15]. In addition, personal
communicationwas used to obtain data from subjects lost to follow-up.
The date of admission was used as the date of the event. Details of each
CV event were obtained from the treating physician. The independent
end point committee of the active trial period reviewed all end points
and the members had no knowledge of the subject's treatment
assignments.
2.3. Measurements
At trial follow-up visits, various clinical and biochemical measure-
ments were performed and two 24-hour urine collections were obtain-
ed. Systolic and diastolic blood pressureswere calculated as themean of
the last two of ten consecutive measurements, using an automatic
Dinamap XL model 9300 series device (Johnson & Johnson Medical
Inc.). Serum creatinine, plasma cholesterol and glucose were deter-
mined in one laboratory by Kodak Ektachem dry chemistry (Eastman
Kodak, Rochester, NY, USA), using an automated enzymatic method.
The intra- and interassay variation coefﬁcient of serum creatinine
were respectively 0.9% and 1.1%. Serum triglycerides were measured
enzymatically. A commercially available assay system was used toassess high-density lipoprotein (HDL) cholesterol (Abbott Inc., Abbott
Park, IL, USA). Urinary albumin concentrations were determined
by nephelometry with a threshold of 2.3 mg/L and intra-assay and
interassay coefﬁcients of variation of less than2.2% and 2.6%, respective-
ly (DadeBehringDiagnostic). 10-year risk for CV events according to the
FRS was calculated as described by D'Agostino [14] and divided into
three risk categories: low (b10%), intermediate (10–20%) and high
(N20%), as recommended by Wilson [16]. UAE was categorized by low
(b50 mg/24 h) vs. high (≥50 mg/24 h), according to the quintiles
used in PREVEND IT [10,13].
2.4. Statistical methods
Baseline continuous data are reported asmean (standard deviation)
for normal data. Normality of variables was assessed by standard nu-
merical methods, using skewness/kurtosis tests. UAE and triglycerides
showed a log-linear functional shape with the response variable and
were transformed to a 2-log scale and reported asmedian (interquartile
range). This means that risk estimates should be interpreted as the rel-
ative risk of values were doubled (e.g. 1 to 2 mg/L or 10 to 20 mg/24 h).
Times to ﬁrst occurrence of outcomes are presented as Kaplan–Meier
estimates, and statistical differences between placebo and active treat-
ments were analyzed by log-rank testing. To assess the additive value
of UAE over the FRS, we evaluated the Integrated Discrimination Im-
provement (IDI) and Net Reclassiﬁcation Improvement (NRI) indices
for UAE (both as a continuous variable as well as dichotomized to high
vs. low, using a cut-off of 50 mg/24 h) according to FRS. All reported
probability values are two-tailed and P b 0.05 was considered as the
nominal level of statistical signiﬁcance. All analyses were performed
using StataIC (version 11.0 software for Windows).
3. Results
Baseline characteristics of subjects divided by low (b50 mg/24 h) vs.
high UAE (≥50 mg/24 h) are summarized in Table 1. These characteris-
tics show a middle-aged population with a low prevalence of conven-
tional CV risk factors, exempliﬁed e.g. by a low prevalence of diabetes
mellitus (4.0%), and little use of CV drugs (3.5%). The subjects in the
high UAE group were at baseline older and had higher levels of systolic
and diastolic blood pressures and a higher resting heart rate. Also, levels
of glucose, triglycerides and serum creatinine were slightly increased in
the high UAE group. Baseline median FRS was 12.7% and was different
between UAE groups, namely 11.9% (IQR 5.2–23.9) and 17.1% (IQR
7.8–30.7) for the low UAE and the high UAE group (P= 0.001), respec-
tively. Mean follow-up was 10.0 years (range 9.8 to 10.3) from start of
the active trial until 1 January 2009.
At baseline, median UAE was 19 mg/24 h (IQR 15–29) in the
low UAE group and 77 mg/24 h (IQR 59–115) for the high UAE group
(P b 0.001). The following changes, during the entire follow-up period
are depicted in Fig. 1. The low and high groups of UAE are divided by
treatment group. In the low UAE group, 4 years of treatment with
fosinopril during the active trial resulted in a decrease in median UAE
from 20 mg/24 h to 15 mg/24 h (P = 0.003 compared to baseline). In
the high UAE group, fosinopril treatment decreased UAE to 55 mg/24 h
(P = 0.003 compared to baseline). Three months after cessation of
fosinopril, median UAE increased in both groups and remained stable
during further follow-up. UAE was unaffected by placebo during the
entire follow-up period.
During the entire follow-up, the primary endpoint occurred in 119
subjects. The event rate in the high UAE group was signiﬁcantly
higher, compared to the low UAE group (22.0% vs. 12.3%, respectively,
P = 0.001). Treatment with fosinopril lowered the event rate in the
high UAE group to the same height as subjects with low UAE levels at
start (15.6% vs. 12.3%, respectively, P = 0.436).
The observed ten-year event rate for both the lowUAE group aswell
as thehighUAE group is plotted against the FRS-predicted risk, in Fig. 2A
Table 1






Variables (N = 665) (N = 168) P-value
Age (yrs) 50 ± 12 54 ± 12 b0.001
Males (%) 65.0 64.9 0.984
Caucasian (%) 96.2 95.8 0.575
Body mass index (kg/m2) 26 ± 4 27 ± 5 0.009
Obesity (N30 kg/m2) 13.9 17.3 0.263
Smoking (%) 39.6 40.5 0.826
Systolic blood pressure (mm Hg) 128 ± 17 135 ± 19 b0.001
Diastolic blood pressure (mm HG) 75 ± 10 78 ± 10 b0.001
Heart rate (bpm) 69 ± 10 71 ± 11 0.034
Cholesterol (mmol/L)
Total 5.8 ± 1.0 5.8 ± 1.1 0.992
HDL 1.0 ± 0.3 1.0 ± 0.3 0.641
LDL 4.1 ± 0.9 4.0 ± 1.0 0.519
Triglycerides (mmol/L) 1.3 (0.9–1.9) 1.5 (1.0–2.1) 0.001
Glucose (mmol/L) 5.1 ± 1.2 5.2 ± 1.3 0.116
eGFR (kg/min/1.73 m2) 83 ± 14 79 ± 15 0.001
Serum creatinine (μmol/L) 83 (75–92) 86 (76–96) 0.034
UAE (mg/24 h) 19.0 (14.0–28.0) 77.0 (59.5–124.5) b0.001
Diabetes mellitus (%) 2.4 3.6 0.400
Prior event (%) 0.0 0.0 NA
Cardiovascular drugs (%) 3.0 5.4 0.138
Aspirin and antiplatelet agents 1.1 1.8 0.101
Beta-blockers 0.6 0.6 0.993
Nitrate 0.0 0.0 NA
Diuretics 0.3 1.8 0.026
Calcium channel blockers 0.8 0.6 0.830
Digoxin 0.6 1.8 0.133
Framingham risk score 11.9 (5.2–23.9) 17.1 (7.8–30.7) 0.001
UAE = Urinary albumin excretion; HDL = High-density lipoprotein; LDL = low-density
lipoprotein; eGFR = estimated glomerular ﬁltration rate; NA = not available.
⁎ Continuous variables are presented asmean ± standard deviation and comparedwith
theuse of Student's t-test, in case of normal distribution. In case of skewed distribution, con-
tinuous variables are presented as median (interquartile range) and compared using the
Kruskall–Wallis test.
Fig. 2. A and B. Predicted Framingham Risk Score compared to Kaplan–Meier estimates of
incidence of cardiovascular events in fosinopril and placebo group, divided by a
UAE b50 mg/24 h and UAE ≥50 mg/24 h.
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identical to the FRS-predicted event rate. There was no effect of
fosinopril on the observed event rate in the low UAE group. In contrast,
the 10 years event rate of subjects in the group UAE ≥50 mg/24 h is
signiﬁcantly underestimated compared to the predicted 10 years
FRS-predicted risk. The event rate almostdoubled, from 17.2% (FRS-
predicted) to 29.5 (observed). Treatment for 4 years with fosinopril
during the active trial period signiﬁcantly reduced the observed CV
risk and outcome compared to placebo, and normalized the actual
CV risk to the FRS-predicted CV risk level (Table 2).Fig. 1.Median urinary albumin excretion (mg/24 h) by treatment and visit. Triangles refer
to placebo group and circles refer to treatment group (fosinopril).The Integrated Discrimination Improvement (IDI) index for includ-
ingUAE to the FRSwas signiﬁcant, P= 0.033 (outcomevariable: prima-
ry endpoint). The area under the curve for the FRS in our sample is 76%
for predicting CV events. Adding UAE to FRS improved the area under
the curve by 0.54% (P = 0.036; c-statistics). In the entire sample, the
NRI of UAE over the FRS was not signiﬁcant (P = 0.313). Given theTable 2
Observed incidence of primary endpoint, divided by UAE groups.
UAE b 50 mg/24 h UAE ≥ 50 mg/24 h
(N = 665) (N = 168)
Placebo Fosinopril P Placebo Fosinopril P
Mortality (N = 343) (N = 322) (N = 78) (N = 90)
All causes 19 (5.5) 23 (7.1) 0.396 10 (12.8) 8 (8.9) 0.411
CV causes 7 (2.0) 6 (1.9) 0.869 4 (5.1) 1 (1.1) 0.126
Hospitalization for
Non fatal MI 21 (6.1) 22 (6.8) 0.710 9 (11.5) 9 (10.0) 0.748
Heart failure 4 (1.2) 6 (1.9) 0.460 4 (5.1) 3 (3.3) 0.561
PVD 5 (1.5) 5 (1.6) 0.920 3 (3.9) 1 (1.1) 0.246
CVA 12 (3.5) 7 (2.2) 0.306 6 (7.7) 2 (2.2) 0.097
Total CV morbidity 39 (11.4) 38 (11.8) 0.862 22 (28.2) 13 (14.4) 0.029
Primary endpoint 42 (12.2) 40 (12.4) 0.945 23 (29.5) 14 (15.6) 0.030
Values are n (%)
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we repeated the NRI analysis in subjects in the high UAE group
(N = 167). This resulted in a reclassiﬁcation of 4.6%, however not sig-
niﬁcant (P = 0.313) (see Supplementary Tables 1A and 1B).
4. Discussion
Previously, the PREVEND IT trial reported on a high CV risk in sub-
jects with elevated UAE (≥50 mg/24 h), with an event rate of almost
30% after 10 years of follow-up [10]. In this sub-analysis we compared
the observed event rate in PREVEND IT with the populations' FRS-
estimated risk. Our results indicate that the FRS substantially underesti-
mates CV risk of subjectswith UAE≥50 mg/24 h and that this increased
risk is amenable to treatment with the ACE inhibitor fosinopril, the use
of which reduced the risk to the FRS-estimated risk. Adding UAE to the
FRS, using a cut point of 50 mg/24 h, furthermore increased the area
under the curve and IDI in risk estimation.
The FRS is themostwell-knownandmostwidely usedmodels for CV
risk stratiﬁcation. Although the FRS does not sufﬁce for speciﬁc risk
groups, for example young or low-risk patients [17], its use for a general
risk prediction for CV disease is undisputed. Still, multiple attempts
have been made to improve CV risk stratiﬁcation by adding variables
to the FRS, like non-invasive vascular assessments [18], coronary artery
calcium score [19], or brachial artery ﬂow-mediated dilation [20], and
several other variables. Limited studies have been done investigating
the additional value of UAE on the FRS. The group of Cao et al. showed
in elderly subjects that the combination of UAE with the Framingham
Risk Score improved risk stratiﬁcation, over a follow-up period of
5.6 years [11]. Other studies used albumin–creatinine ratio alone, or in
combination with other biomarkers to improve FRS [21,22].
In the current analysis, we compared the predicted 10-year CV risk
to the observed event rate during follow-up. For subjects with an UAE
b50 mg/24 h, the FRS proved to be very accurate. In contrast, subjects
in the highest UAE quintile (≥50 mg/24 h) were substantially
underestimated with regard to their CV risk. The addition of UAE
≥50 mg/24 h to the FRS increased the IDI and area under the curve
signiﬁcantly, implying additional value in predicting individual 10-year
CV risk. This is strengthened by the observed high incidence of CV events
in subjects in the highest quintile of UAE. In addition, the increased
rate of observed CV events was neutralized in the group treated with
fosinopril. Fosinopril-treated subjects also showed a signiﬁcant decrease
in UAE during the active trial period, while there was little effect of
fosinopril treatment on blood pressure [13].
We however did not ﬁnd any additional value of UAE over the FRS
using NRI, which can be explained by several factors. The IDI differs
from the NRI in that the population is not cross-classiﬁed by ﬁxed levels
from the two prediction models. The conventional and widely used risk
categories used in this analysis (b10%; 10–20%; N20%) might not have
been suitable for assessing additional value of UAE. Also, the baseline
average FRS for subjects in PREVEND IT is 12.7%, which is already
considerably increased. This is due to the relative high percentage of
tobacco users and an average systolic blood pressure of 129 mm Hg at
baseline in PREVEND IT. The lack of additional value of UAE might be
caused by the already present high baseline risk for CV disease. Finally,
theNRIwas performed in the total sample and the sub-group of subjects
with UAE ≥50 mg/24 h, however irrespectively of treatment group.
This could have diluted the additional value of UAE, while the subjects
treated with fosinopril compared to placebo had less CV events during
follow-up. Our studywas unfortunately underpowered to assess thedif-
ference in added value of UAE over FRS for both treatment groups
separately.
5. Study limitations
The study sample in this trial had a relatively low CV risk. Less than
3% of the participants were diabetic, and evidence of prior cardiacevents such as myocardial infarction, bypass surgery, or heart failure
was all b1% each. In line with this, the number of cardiovascular events
was low. The sample size of PREVEND IT does not allowmaking deﬁnite
statements about the role of UAE in prediction CV risk. We used the FRS
as standard method of evaluation cardiovascular risk, despite the fact
that this score refers to the US population. Risk scores may be subject
to bias, however the FRS is generally assumed to be an accurate score
and is widely used.
6. Conclusions
In the subjects with elevated UAE (≥50 mg/24 h) the actual 10-year
CV risk was signiﬁcantly higher than predicted by FRS, and this excess
risk was neutralized by fosinopril treatment. The FRS should be used
carefully in subjects with increased levels of UAE, as it underestimates
their CV risk.
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